購読する
モデル製品
サービス
前臨床薬効評価
コミュ二ティー
Gla KO Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
Gla KO Mouse
製品名
Gla KO Mouse
製品ID
I001223
系統名
C57BL/6NCya-Glaem1/Cya
背景情報
C57BL/6NCya
状況
このマウス系統を論文で使用する場合は、「Gla KO Mouse(カタログ番号I001223)はサイアジェンから購入しました。」と引用してください。
Disease Animal Models
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
Disease Animal Models
基本情報
検証 Data
関連リソース
基本情報
遺伝子名
遺伝子別名
Ags
NCBI ID
染色体
Chr X
MGI ID
さらに
系統詳細
Fabry Disease (FD) is a rare genetic lysosomal storage disorder caused by mutations in the GLA gene on the X chromosome, leading to a deficiency in lysosomal α-galactosidase A (α-GalA) activity. The absence of α-GalA results in the accumulation of the metabolic substrate globotriaosylceramide (GL3) in multiple organs, ultimately causing organ damage. In severe cases, this may lead to cardiovascular complications, end-stage renal disease, and even early death [1]. Clinically, FD is divided into early-onset (typical) and late-onset (attenuated) forms. Early-onset patients almost completely lose α-GalA activity and experience multi-organ damage early in life, while late-onset patients retain some enzyme activity, with symptom severity dependent on the residual enzyme activity [1-2]. Since the GLA gene is located on the X chromosome, male patients typically experience more severe symptoms. Current treatment options include enzyme replacement therapy (ERT) and molecular chaperone therapy (migalastat), but due to high costs and various limitations on efficacy, new therapeutic strategies are urgently needed [3]. In preclinical studies, Gla knockout (KO) mice have become the "gold standard" for studying the mechanisms of FD and evaluating therapies [4]. Gla KO mice exhibit GL3 accumulation in various tissues with aging, and their histological changes closely mimic the pathological features seen in human FD patients. It is widely used in research on enzyme replacement therapy, AAV gene therapy, and substrate reduction therapy [5-13].
This strain is a Gla gene knockout (KO) mouse model of Fabry Disease, created using gene editing technology to knockout the Gla gene on the X chromosome of mice (the homolog of the human GLA gene). The deletion of the Gla gene results in the absence of Gla gene expression and α-GalA activity. This model can be widely used for studying the mechanisms of Fabry Disease, assessing the efficacy and safety of potential therapies, and investigating lysosomal-related metabolic disorders and their pathophysiological effects.
参考文献
Chan B, Adam DN. A Review of Fabry Disease. Skin Therapy Lett. 2018 Mar;23(2):4-6.
Lerario S, Monti L, Ambrosetti I, Luglio A, Pietra A, Aiello V, Montanari F, Bellasi A, Zaza G, Galante A, Salera D, Capelli I, La Manna G, Provenzano M. Fabry disease: a rare disorder calling for personalized medicine. Int Urol Nephrol. 2024 Apr 13.
Lenders M, Brand E. Fabry disease - a multisystemic disease with gastrointestinal manifestations. Gut Microbes. 2022 Jan-Dec;14(1):2027852.
Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, Cardarelli CO, Sugimoto Y, Pastan I, Gottesman MM, Brady RO, Kulkarni AB. alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2540-4.
4D molecular therapeutics. An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adult Males with Fabry Disease. Retrieved April 18, 2024, from 4DMT PPT Template (4dmoleculartherapeutics.com)
Jeyakumar JM, Kia A, Tam LCS, McIntosh J, Spiewak J, Mills K, Heywood W, Chisari E, Castaldo N, Verhoef D, Hosseini P, Kalcheva P, Cocita C, Miranda CJ, Canavese M, Khinder J, Rosales C, Hughes D, Sheridan R, Corbau R, Nathwani A. Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease. Gene Ther. 2023 Jun;30(6):487-502.
Shen JS, Arning E, West ML, Day TS, Chen S, Meng XL, Forni S, McNeill N, Goker-Alpan O, Wang X, Ashcraft P, Moore DF, Cheng SH, Schiffmann R, Bottiglieri T. Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease. Hum Mol Genet. 2017 Mar 15;26(6):1182-1192.
uniQure. Patient enrollment in the clinical trial of AMT-191, uniQure’s gene therapy candidate for the treatment of Fabry disease, is expected to begin in the first half of 2024. Retrieved April 18, 2024, from Fabry Disease | Programs & Pipeline | uniQure
Pagant S, Huston MW, Moreira L, Gan L, St Martin S, Sproul S, Holmes MC, Meyer K, Wechsler T, Desnick RJ, Yasuda M. ZFN-mediated in vivo gene editing in hepatocytes leads to supraphysiologic α-Gal A activity and effective substrate reduction in Fabry mice. Mol Ther. 2021 Nov 3;29(11):3230-3242.
Yasuda M, Huston MW, Pagant S, Gan L, St Martin S, Sproul S, Richards D, Ballaron S, Hettini K, Ledeboer A, Falese L, Cao L, Lu Y, Holmes MC, Meyer K, Desnick RJ, Wechsler T. AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction. Mol Ther Methods Clin Dev. 2020 Jul 9;18:607-619.
Takahashi H, Hirai Y, Migita M, Seino Y, Fukuda Y, Sakuraba H, Kase R, Kobayashi T, Hashimoto Y, Shimada T. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13777-82.
PR Newswire. CANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract at ESGCT 30th Annual Congress. Retrieved April 18, 2024, from CANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract at ESGCT 30th Annual Congress (prnewswire.com)
Ziegler RJ, Cherry M, Barbon CM, Li C, Bercury SD, Armentano D, Desnick RJ, Cheng SH. Correction of the Biochemical and Functional Deficits in Fabry Mice Following AAV8-mediated Hepatic Expression of α-galactosidase A. Mol Ther. 2007 Mar;15(3):492-500.
系統作製戦略
Exons 2-5 of the Gla gene in the mouse X chromosome were knocked out using gene editing technology.

Figure 1. Gene editing strategy of Gla KO mice.
適用分野
Mechanistic studies and therapeutic evaluations of Fabry Disease (FD);
Research on α-GalA function and related metabolic pathways;
Studies on lysosomal structure and function, and exploration of diseases caused by lysosomal defects.
検証 Data
関連リソース
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
